EA201491749A1 - Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение - Google Patents
Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применениеInfo
- Publication number
- EA201491749A1 EA201491749A1 EA201491749A EA201491749A EA201491749A1 EA 201491749 A1 EA201491749 A1 EA 201491749A1 EA 201491749 A EA201491749 A EA 201491749A EA 201491749 A EA201491749 A EA 201491749A EA 201491749 A1 EA201491749 A1 EA 201491749A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hydroxymethyl
- tris
- glp1r
- aminomethane salts
- agonist
- Prior art date
Links
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 title abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614265P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/033091 WO2013142569A1 (en) | 2012-03-22 | 2013-03-20 | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201491749A1 true EA201491749A1 (ru) | 2015-01-30 |
Family
ID=49223316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491749A EA201491749A1 (ru) | 2012-03-22 | 2013-03-20 | Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9198901B2 (enExample) |
| EP (1) | EP2854526B1 (enExample) |
| JP (1) | JP2015510947A (enExample) |
| KR (1) | KR102158992B1 (enExample) |
| CN (1) | CN104202977A (enExample) |
| AU (1) | AU2013235167B2 (enExample) |
| CA (1) | CA2868033A1 (enExample) |
| EA (1) | EA201491749A1 (enExample) |
| ES (1) | ES2674951T3 (enExample) |
| HK (1) | HK1199371A1 (enExample) |
| IL (1) | IL234615B (enExample) |
| IN (1) | IN2014DN07867A (enExample) |
| MX (1) | MX352804B (enExample) |
| NZ (1) | NZ629203A (enExample) |
| SG (1) | SG11201405353VA (enExample) |
| WO (1) | WO2013142569A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217165A1 (en) * | 2018-05-08 | 2019-11-14 | Vtv Therapeutics Llc | Therapeutic uses of glp1r agonists |
| EP4130005A4 (en) * | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| CN115315426B (zh) * | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU718030B2 (en) * | 1996-05-20 | 2000-04-06 | G.D. Searle & Co. | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations |
| AR024076A1 (es) * | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Sales de cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil) ciclohexan-1-carboxilato] |
| EP1363913A2 (en) * | 2001-02-05 | 2003-11-26 | Dr. Reddy's Laboratories Ltd. | Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| EP1439834A1 (en) * | 2001-10-30 | 2004-07-28 | Applied Research Systems ARS Holding N.V. | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) |
| BRPI0409501A (pt) * | 2003-04-18 | 2006-04-18 | Incyte San Diego Inc | compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças |
| EA018225B1 (ru) * | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| CA2726610C (en) * | 2008-06-05 | 2015-05-05 | Asahi Kasei Pharma Corporation | Sulfonamide compounds and use thereof |
| DK2370440T3 (en) * | 2008-12-08 | 2014-12-08 | Glaxosmithkline Llc | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases |
| WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
-
2013
- 2013-03-20 EP EP13765015.6A patent/EP2854526B1/en active Active
- 2013-03-20 SG SG11201405353VA patent/SG11201405353VA/en unknown
- 2013-03-20 KR KR1020147026362A patent/KR102158992B1/ko active Active
- 2013-03-20 AU AU2013235167A patent/AU2013235167B2/en active Active
- 2013-03-20 CA CA2868033A patent/CA2868033A1/en not_active Abandoned
- 2013-03-20 CN CN201380015508.2A patent/CN104202977A/zh active Pending
- 2013-03-20 NZ NZ629203A patent/NZ629203A/en not_active IP Right Cessation
- 2013-03-20 WO PCT/US2013/033091 patent/WO2013142569A1/en not_active Ceased
- 2013-03-20 JP JP2015501876A patent/JP2015510947A/ja not_active Ceased
- 2013-03-20 IN IN7867DEN2014 patent/IN2014DN07867A/en unknown
- 2013-03-20 EA EA201491749A patent/EA201491749A1/ru unknown
- 2013-03-20 HK HK14112910.6A patent/HK1199371A1/xx unknown
- 2013-03-20 MX MX2014010366A patent/MX352804B/es active IP Right Grant
- 2013-03-20 ES ES13765015.6T patent/ES2674951T3/es active Active
-
2014
- 2014-09-11 IL IL234615A patent/IL234615B/en not_active IP Right Cessation
- 2014-09-18 US US14/489,890 patent/US9198901B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2854526A4 (en) | 2016-02-24 |
| SG11201405353VA (en) | 2014-09-26 |
| CA2868033A1 (en) | 2013-09-26 |
| CN104202977A (zh) | 2014-12-10 |
| AU2013235167A1 (en) | 2014-09-18 |
| US9198901B2 (en) | 2015-12-01 |
| AU2013235167B2 (en) | 2017-03-30 |
| ES2674951T3 (es) | 2018-07-05 |
| HK1199371A1 (en) | 2015-07-03 |
| MX2014010366A (es) | 2015-05-15 |
| IN2014DN07867A (enExample) | 2015-04-24 |
| MX352804B (es) | 2017-12-08 |
| KR102158992B1 (ko) | 2020-09-23 |
| KR20140138758A (ko) | 2014-12-04 |
| JP2015510947A (ja) | 2015-04-13 |
| NZ629203A (en) | 2015-12-24 |
| WO2013142569A1 (en) | 2013-09-26 |
| EP2854526B1 (en) | 2018-04-25 |
| IL234615B (en) | 2018-02-28 |
| ES2674951T8 (es) | 2018-08-23 |
| US20150005339A1 (en) | 2015-01-01 |
| EP2854526A1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
| BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
| EA201170772A1 (ru) | Органические соединения | |
| BRPI0908637B8 (pt) | composto e composição farmacêutica do mesmo | |
| BR112014033080A2 (pt) | inibidores do vírus da hepatite c | |
| BR112018003595A2 (en) | 6-6 bicyclic aromatic ring substituted nucleoside analogs for use as prmt5 inhibitors | |
| BR112018076169A2 (pt) | derivados azabenzimidazol como inibidores de pi3k beta | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2011000087A1 (es) | Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad. | |
| BR112016028835A2 (pt) | derivados de auristatina e conjugados dos mesmos | |
| CR20120634A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| EA201591632A1 (ru) | Цитотоксические и антимитотические соединения и способы их применения | |
| EA201492011A1 (ru) | Безводные фармацевтические составы для местного применения | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112015012720A2 (pt) | derivados de feniletilpiridina como inibidores de pde4 | |
| EA201500821A1 (ru) | Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов | |
| BR112014017735A8 (pt) | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto | |
| BR112018007068A2 (pt) | derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta | |
| EA201600122A1 (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112015012716A2 (pt) | derivados de feniletilpiridina como inibidores de pde4 | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| CY1117210T1 (el) | Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης | |
| MA37645A2 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 |